Key Takeaways
- • Blackstone, Carlyle, and Hellman & Friedman acquire majority stake in Medline Industries for $34 billion in leveraged buyout, reportedly the largest LBO in a decade, with the transaction including $17 billion in equity and structured to close by year-end 2021.
- • Medline bested competing bids from Brookfield Asset Management and a Bain Capital-led consortium, narrowing from at least eight bidders in May to three finalists by June, with Singapore's sovereign wealth fund GIC co-investing alongside the PE trio.
- • Mills family retains largest shareholder position and operational control: CEO Charlie Mills and senior management team remain in place; company stays privately held post-close, maintaining independence from financial engineering pressures typical in leveraged structures.
- • $17.5 billion in 2020 revenue and 28,000-employee global footprint position Medline as dominant healthcare supplies distributor, with products spanning hospital-grade equipment (wheelchairs, beds, anesthesia supplies) to consumer brands like Curad across 110+ countries.
- • Capital deployment targets international expansion and supply chain fortification, signaling PE consortium strategy to unlock growth in fragmented global medical supply markets rather than pursue aggressive cost-cutting or portfolio consolidation.
Summary
A consortium led by Blackstone Group, Carlyle Group, and Hellman & Friedman has agreed to acquire a majority stake in Medline Industries, the Northfield, Illinois-based medical supply manufacturer, in a $34 billion leveraged buyout announced on June 5, 2021. The transaction, valued at more than $30 billion in base equity consideration with $34 billion inclusive of debt financing, represents one of the largest LBOs executed in the post-financial crisis era. According to Bloomberg, the deal structure includes a $17 billion equity check from the PE consortium. Singapore's GIC sovereign wealth fund is also participating as a co-investor in the transaction.
The acquisition culminated a competitive sales process that began in April 2021, during which Medline attracted substantial bidder interest. Multiple sources indicate the company initially drew at least eight qualified bidders before the field narrowed to three finalists by June—including the winning Blackstone-Carlyle-Hellman & Friedman partnership, a consortium anchored by Bain Capital, and a bid from Canadian investment firm Brookfield Asset Management. The eventual winner outcompeted Brookfield in final-round bidding, reflecting strong appetite from mega-cap PE platforms for healthcare infrastructure assets in a low-rate environment.
Medline's scale and market position underpin deal economics and strategic rationale. The company generated $17.5 billion in revenue during 2020 and employs 28,000 people globally, operating as the largest privately held manufacturer and distributor of healthcare supplies in the United States. Its product portfolio spans hospital-critical items—anesthesia, gowns, wheelchairs, beds, lab supplies—and consumer-facing brands including the Curad line, with distribution reaching over 110 countries. This diversified geographic footprint and end-market exposure position Medline for value creation through operational scaling and international market penetration.
Management and ownership continuity reflects a family-office partnership model rather than traditional PE-driven restructuring. The Mills family, which founded Medline in 1966, will retain the largest single shareholder stake post-close. CEO Charlie Mills, his cousin Andy Mills (President), and COO Jim Abrams will remain in their executive roles. Medline confirmed that the entire senior management team stays intact, with the company remaining privately held. Management and the PE sponsors have flagged capital deployment toward accelerating international expansion and strengthening global supply chain resilience—priorities aligned with post-pandemic healthcare infrastructure investment trends and supply-side vulnerabilities exposed in 2020–2021.
The acquisition culminated a competitive sales process that began in April 2021, during which Medline attracted substantial bidder interest. Multiple sources indicate the company initially drew at least eight qualified bidders before the field narrowed to three finalists by June—including the winning Blackstone-Carlyle-Hellman & Friedman partnership, a consortium anchored by Bain Capital, and a bid from Canadian investment firm Brookfield Asset Management. The eventual winner outcompeted Brookfield in final-round bidding, reflecting strong appetite from mega-cap PE platforms for healthcare infrastructure assets in a low-rate environment.
Medline's scale and market position underpin deal economics and strategic rationale. The company generated $17.5 billion in revenue during 2020 and employs 28,000 people globally, operating as the largest privately held manufacturer and distributor of healthcare supplies in the United States. Its product portfolio spans hospital-critical items—anesthesia, gowns, wheelchairs, beds, lab supplies—and consumer-facing brands including the Curad line, with distribution reaching over 110 countries. This diversified geographic footprint and end-market exposure position Medline for value creation through operational scaling and international market penetration.
Management and ownership continuity reflects a family-office partnership model rather than traditional PE-driven restructuring. The Mills family, which founded Medline in 1966, will retain the largest single shareholder stake post-close. CEO Charlie Mills, his cousin Andy Mills (President), and COO Jim Abrams will remain in their executive roles. Medline confirmed that the entire senior management team stays intact, with the company remaining privately held. Management and the PE sponsors have flagged capital deployment toward accelerating international expansion and strengthening global supply chain resilience—priorities aligned with post-pandemic healthcare infrastructure investment trends and supply-side vulnerabilities exposed in 2020–2021.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.